© 2020 MJH Life Sciences and Cure Today. All rights reserved.
© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.
January 20th 2020, 9:28pm
As a guest speaker at the 2019 MPN Heroes ® Recognition Ceremony, Dr. David C. Fajenbaum had the chance to discuss how translational research is a vital part of getting the right treatment to patients with cancer.
January 17th 2020, 12:00am
Emergency room visits are costly and take a lot of time patients with cancer don’t have, which is why the creation of a 24-hour clinic to address cancer related symptoms and treatment side effects could prove vital for patients.
January 14th 2020, 7:01pm
Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.
January 14th 2020, 12:37am
For Natalie Catalano, caregiving for her daughter with essential thrombocythemia included not only being a rock of support, but also being a vocal advocate for her daughter’s care team to make the right diagnosis.
January 11th 2020, 3:00am
Madeleine Henriquez noticed that the mental health care of patients with MPN was being overlooked and took action in a way that has changed her community for the better.
January 6th 2020, 7:00pm
Patients with rare blood cancers are not all the same, and this understanding has helped Dr. Irum Khan become an advocate for people with these conditions — and an MPN Hero.
December 16th 2019, 11:00pm
At the 2019 MPN Heroes® event Tammy Matuska, B.S.N., RN, known as the "lifeline to patients," was honored for her outstanding work for patients with MPN.
December 12th 2019, 6:58pm
As a 20-something med student facing a rare disease, Dr. David C. Fajgenbaum took matters into his own hands to find his own treatment.
December 7th 2019, 7:00pm
At the annual MPN Heroes event, Dr. David Fajgenbaum, who discovered a treatment for his own rare disorder, shared insights on turning hope into action when faced with adversity.
November 26th 2019, 9:00pm
Here is a list of the recent trial initiations that occurred within the myeloproliferative neoplasm cancer space.